View in EDS HTML Full Text PDF Full Text

Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.

Saved in:
Bibliographic Details
Title: Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.
Authors: Lustig M; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany., Hahn C; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway., Leangen Herigstad M; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway., Andersen JT; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway., Leusen JHW; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands., Burger R; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany., Valerius T; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.
Source: Frontiers in oncology [Front Oncol] 2024 Nov 26; Vol. 14, pp. 1488668. Date of Electronic Publication: 2024 Nov 26 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39659795
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lustig+M%22">Lustig M</searchLink>; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Hahn+C%22">Hahn C</searchLink>; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Leangen+Herigstad+M%22">Leangen Herigstad M</searchLink>; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Andersen+JT%22">Andersen JT</searchLink>; Institute for Clinical Medicine, Department of Pharmacology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Institute for Clinical Medicine, Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance (PRIMA), University of Oslo, Oslo, Norway.<br /><searchLink fieldCode="AU" term="%22Leusen+JHW%22">Leusen JHW</searchLink>; Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Burger+R%22">Burger R</searchLink>; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Valerius+T%22">Valerius T</searchLink>; Division of Stem Cell Transplantation and Cellular Immunotherapies, Department of Medicine II, University Medical Center Schleswig-Holstein and Christian-Albrechts-University Kiel, Kiel, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2024 Nov 26; Vol. 14, pp. 1488668. <i>Date of Electronic Publication: </i>2024 Nov 26 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39659795
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2024.1488668
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1488668
    Titles:
      – TitleFull: Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lustig M
      – PersonEntity:
          Name:
            NameFull: Hahn C
      – PersonEntity:
          Name:
            NameFull: Leangen Herigstad M
      – PersonEntity:
          Name:
            NameFull: Andersen JT
      – PersonEntity:
          Name:
            NameFull: Leusen JHW
      – PersonEntity:
          Name:
            NameFull: Burger R
      – PersonEntity:
          Name:
            NameFull: Valerius T
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 26
              M: 11
              Text: 2024 Nov 26
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1